Rare Disease

News

Atrasentan data backs up Novartis’ $3.5bn Chinook deal

Novartis’ bid to build a strong presence in the treatment of rare kidney disease IgA nephropathy (IgAN) has been boosted by phase 3 data with atrasentan, the main asset in

Market Access

Understanding the complex rare disease and specialty pharmac...

Donovan Quill, AscellaHealth’s Executive Vice President of Growth and Strategy, describes the unique challenges associated with bringing new specialty and rare disease pharmaceutical produc

News

AnaptysBio draws a bead on Bayer’s Spevigo after phase 3 win

After disappointing results in other indications, AnaptysBio has a route to market with its IL-36 receptor inhibitor imsidolimab in a rare and life-threatening form of the

News

Scotland first in Europe to back MSD drug for VHL tumours

Scotland has become the first country in Europe to recommend coverage of MSD’s Welireg as a treatment for some people with von Hippel-Lindau disease (VHL), a rare genetic

R&D